QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients

Lancet

Volumn 355, Issue 9209, 2000, Pages 1048-1052

  Reilly, J G ^a,b,c   Ayis, S A ^b   Ferrier, I N ^a   Jones, S J ^b   Thomas, S H L ^b  

^a Academic Department of Psychiatry   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c NATIONAL HEALTH SERVICE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORPROMAZINE; CLOZAPINE; DROPERIDOL; FLUPHENAZINE; HALOPERIDOL; LITHIUM; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PROCYCLIDINE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SULPIRIDE; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ELECTROCARDIOGRAM; FEMALE; HEART ARRHYTHMIA; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL PATIENT; PRIORITY JOURNAL; QT INTERVAL; REGRESSION ANALYSIS; RISK; SUDDEN DEATH;

EID: 0034712552     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02035-3     Document Type: Article

References (26)

1. Newman S.C., Bland R.C. Mortality in a cohort of patients with schizophrenia. a record linkage study Can J Psychiatr. 36:1991;239-245.
2. Thomas S.H. Drugs, QT interval abnormalities and ventricular arrhythmias. Adverse Drug React Toxicol Rev. 13:1994;77-102.
3. The association between antipsychotic drugs and sudden death. Council report CR57. 1997;Royal College of Psychiatrists, London.
4. Henderson R.A., Lane S., Henry J.A. Life-threatening ventricular arrhythmia (torsade de pointes) after haloperidol overdose. Hum Exp Toxicol. 10:1991;59-62.
5. Liberatore M.A., Robinson D.S. Torsade de pointes: a mechanism for sudden death associated with neuroleptic drug therapy? J Clin Psychopharmacol. 4:1984;143-146.
6. Faber T.S., Zehender M., Just H. Drug-induced torsade de pointes. incidence, management and prevention Drug Saf. 11:1994;463-476.
7. Algra A., Tijssen J., Roelandt J.et al. QTc prolongation measured by standard 12 lead electrocardiogram is an independent risk factor for sudden death. Circulation. 83:1991;1888-1894.
8. Hii T.Y., Wise D.G., Gillis A.M.et al. Precordial QT interval dispersion as a marker of torsade de pointes. Circulation. 86:1992;1376-1382.
9. Thompson C. Consensus statement. the use of high dose antipsychotic medication Br J Psychiatry. 164:1994;448-458.
10. Warner J.P., Barnes T.R.E., Henry J.A. Electrocardiographic changes in patients receiving neuroleptic medication. Acta Psychiatr Scand. 93:1996;311-313.
11. Barnett A.A. Safety concerns over antipsychotic drug, sertindole. Lancet. 348:1996;256.
12. Rey M.-J., Schultz P., Costa C., Dick P., Tissot R. Guidelines for the dosage of neuroleptics: I. Chlorpromazine equivalents of orally administered neuroleptics. Int Clin Psychopharmacol. 4:1989;95-104.
13. Schultz P., Rey M-J., Dick P., Tissot R. Guidelines for the dosage of neuroleptics: II. Changing from daily oral to long acting injectable neuroleptics. Int Clin Psychopharmacol. 4:1989;105-114.
14. Atkins M., Burgess A., Bottomley C., Riccio M. Chlorpromazine equivalents. a consensus of opinion for both clinical and research applications Psychiatr Bull. 21:1997;224-226.
15. Day C.P., McComb J.M., Campbell R.W.F. QT dispersion. an indication of arrhythmia risk in patients with long QT intervals Br Heart J. 63:1990;342-344.
16. Hartigan-Go K., Bateman D.N., Thomas S.H.L. Inter and intra-observer errors in the measurement of the QT interval and QT dispersion. Br J Clin Pharmacol. 39:1995;104P-105P.
17. Giardina E.G.V., Bigger J.T., Glassman A.H., Perel J.M., Kantor S.J. The electrocardiographic and antiarrhythmic effects of imipramine hydrochloride at therapeutic plasma concentrations. Circulation. 60:1979;1045-1052.
18. Lawrence K.R., Nasraway S.A. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill. a review of the literature Pharmacotherapy. 17:1997;531-537.
19. Huston J.R., Bell G.E. The effect of thioridazine hydrochloride and chlorpromazine on the electrocardiogram. JAMA. 198:1966;134-138.
20. Donatini B., Le Blaye I., Krupp P. Transient cardiac pacing is insufficiently used to treat arrhythmia associated with thioridazine. Cardiology. 81:1992;340-341.
21. Drolet B., Vincent F., Rail J.et al. Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. J Pharmacol Exp Ther. 288:1999;1261-1268.
22. Hartigan-Go K., Bateman D.N., Nyberg G., Martensson E., Thomas S.H. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin Pharmacol Ther. 60:1996;543-553.
23. Kirchner V., Kelly C.A., Harvey R.J. A systematic review of the evidence for the safety and efficacy of thioridazine in dementia. In: Cochrane Library, issue 4. 1998;Update Software, Oxford.
24. Mitchell J.E., Mackenzie T.B. Cardiac effects of lithium therapy in man. A review. J Clin Psychiatr. 43:1982;47-51.
25. Barr C.S., Naas A., Freeman M., Lang C.C., Struthers A.D. QT dispersion and sudden unexpected death in chronic heart failure. Lancet. 343:1994;327-329.
26. Kautzner J., Gang Y.i., Camm A.J., Malik M. Short- and long-term reproducibility of QT, QTc and QT dispersion measurement in healthy subjects. Pacing Electrocardiogr. 17:1994;928-937.